Search research articles
Contact Us
Filters
Showing results (61-70 of 100) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1985
Low-dose deoxycoformycin in lymphoid malignancy
M R Grever, J M Leiby, E H Kraut, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1994
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL
M E Dolan, A E Pegg, R C Moschel, et al.
Cancer Treatment Reports
|
July 1, 1987
Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study
D H Ryan, K J Kopecky, D Head, et al.
Blood
|
August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
J C Byrd, C Shinn, R Ravi, et al.
Journal of the National Cancer Institute
|
September 18, 1991
Summary of the workshop on Drug Development, Biological Diversity, and Economic Growth
J Schweitzer, F G Handley, J Edwards, et al.
Journal of the National Cancer Institute
|
December 21, 1994
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model
J J Casciari, M G Hollingshead, M C Alley, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
B F Chu, M J Karpenko, Z Liu, et al.
Blood
|
March 1, 1981
The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy
M R Grever, M F Siaw, W F Jacob, et al.
Seminars in Oncology
|
July 6, 2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders
J C Byrd, M R Grever, J K Waselenko, et al.
Journal of the National Cancer Institute
|
January 4, 1995
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton
A M Senderowicz, G Kaur, E Sainz, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 100) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1985
Low-dose deoxycoformycin in lymphoid malignancy
M R Grever, J M Leiby, E H Kraut, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1994
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL
M E Dolan, A E Pegg, R C Moschel, et al.
Cancer Treatment Reports
|
July 1, 1987
Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study
D H Ryan, K J Kopecky, D Head, et al.
Blood
|
August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
J C Byrd, C Shinn, R Ravi, et al.
Journal of the National Cancer Institute
|
September 18, 1991
Summary of the workshop on Drug Development, Biological Diversity, and Economic Growth
J Schweitzer, F G Handley, J Edwards, et al.
Journal of the National Cancer Institute
|
December 21, 1994
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model
J J Casciari, M G Hollingshead, M C Alley, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
B F Chu, M J Karpenko, Z Liu, et al.
Blood
|
March 1, 1981
The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy
M R Grever, M F Siaw, W F Jacob, et al.
Seminars in Oncology
|
July 6, 2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders
J C Byrd, M R Grever, J K Waselenko, et al.
Journal of the National Cancer Institute
|
January 4, 1995
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton
A M Senderowicz, G Kaur, E Sainz, et al.
Page
of 10